3E Bioventures Capital Joins $50M Series B For OncoC4

OncoC4 Locks in $50 Million Series B to Advance Cancer Drug Pipeline

OncoC4 has secured nearly $50 million in fresh funding, closing its Series B round with GBA Fund at the helm and strong participation from existing backers HM Capital, 3E Bioventures Capital, Kaitai Capital, along with contributions from the company’s co-founders.The investment marks a major push for the Rockville-based biotech as it ramps up clinical programs targeting cancer and neurodegenerative diseases.Founded in 2020 by immunologists Dr. Y…

3E Bioventures Capital Joins $50M Series B For OncoC4

OncoC4, a clinical-stage biotechnology company, today announced the recent closing of a Series B financing round of nearly $50 million. The round was led by GBA Fund, and supported by additional capital from the Company’s co-founders and existing investors, including HM Capital, 3E Bioventures Capital and Kaitai Capital. OncoC4 was founded in 2020 by two renowned immunologists and serial entrepreneurs, Dr. Yang Liu and Dr. Pan Zheng. By leveragi…